Sarepta Therapeutics, Inc. SRPT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Efficiency | |||||
| Asset turnover | 0.6×— | —— | 0.4×+0.1× | 0.3×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.3×-1.9× | 4.2×+0.3× | 3.9×-0.2× | 4.1×-1.6× | |
| Quick ratio | 2.1×-1.8× | 3.9×+0.3× | 3.7×-0.2× | 3.9×-1.5× | |
| Cash ratio | 0.7×-0.8× | 1.5×+0.9× | 0.7×-0.9× | 1.6×-3.1× | |
| Leverage | |||||
| Debt-to-equity | 0.2×0.0× | 0.1×-0.2× | 0.3×+0.1× | 0.2×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | |
| Valuation | |||||
| Market capitalization | $2.26B-80.6% | $11.61B+28.7% | $9.03B-20.7% | $11.38B+44.9% | |
| Enterprise value | $1.66B-84.5% | $10.72B+20.9% | $8.86B-15.5% | $10.49B+80.9% | |
| Price / sales | 1×— | —— | 7.3×-4.9× | 12.2×+1.0× | |
| Price / book | 2×-5.6× | 7.6×-2.9× | 10.5×-19.1× | 29.6×+21.1× | |
| EV / sales | 0.8×— | —— | 7.1×-4.1× | 11.2×+3.0× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sarepta Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.